Convalescent Plasma Therapy: a Possible Treatment of COVID-19 Pandemic
Keywords:
COVID-19, Coronavirus, Alternative Therapy, Convalescent Plasma TherapyAbstract
COVID 19 is a newly recognized infectious disease that has rapidly spread with no verified treatment available. It is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2). In Convalescent plasma therapy, the yellowish liquid or the plasma from the recovered blood is used to treat the patient suffering from the same illness. For more than 100 years it has been used to treat severe infections with varying degrees of success. For this present infection, multiple clinical trials on plasma therapy are still under vigorous investigation. Despite the very low chance of risks like allergies, lung damage, and transmission of blood-related infection, the therapy has shown a positive result in the recovery of the patients. Many experts are observing its use as a “stopgap measure” until effective vaccines and antiviral drugs are available in a wide range. However, the main challenges faced are finding suitable donors, its expensiveness in the whole procedure, and the inability to perform on a large scale. In this commentary, summarization of the convalescent plasma therapy is done as a hopeful alternative therapy of severe or critical COVID 19. It has also emphasized the promising results shown since the past while the use of this therapy in various infectious diseases.
Downloads
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2020 Shubha Devi Sapkota

This work is licensed under a Creative Commons Attribution 4.0 International License.
The author(s) retain the ownership of the copyrights for their work published in EJMS without any restrictions. Upon submission, the author(s) grants EJMS a license to publish, including to display, store, copy, and reuse the published content.
License to Publish
By submitting a manuscript to EJMS, the author(s) grant the journal a non-exclusive license to:
- Publish and distribute the content in all formats, media, and platforms (both existing and future), while identifying EJMS as the original publisher.
- Reproduce, display, and store the content in both print and online formats, including institutional and digital repositories.
- Translate, adapt, and summarize the work, including reprints, extracts, and abstracts.
- Develop derivative works based on the original content.
- Include the work in electronic databases and provide links to third-party materials.
Creative Commons Licensing
In addition to EJMS’s publishing rights, authors grant third parties the right to use, share, and distribute their work under the Creative Commons Attribution 4.0 (CC BY 4.0) International License. This allows unrestricted use of the content, provided proper attribution is given to the original author(s) and the journal.